Original Research and the Latest News

Who’s Winning the Pharmaceutical R&D Pipeline Race in 2025

The leaders, the contenders, and the strategies for success As we approach the 4th quarter of 2025, let’s review where the pharmaceutical industry’s leading companies rank in terms of overall pipeline strength.Roche, AstraZeneca, and Bristol-Myers Squibb sit in a...

How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%

Unlocking Next-Gen POS Forecasting for Biopharma Success In the high-stakes world of biopharma, advanced Probability of Success (POS) forecasting can revolutionize the landscape of clinical trials. By adopting next-gen POS forecasting models, companies can...

Not Your Grandparents’ Probability of Success Forecasts

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

Recent Posts

Recent Tweets

When life feels like it's not going well...

Recovery Score (Guideline)
・Clean your room.    18%
・Watch a Ghibli movie. 26%
・Get morning sunlight l. 33%
・Keep a journal.     41%
・Read one moving book. 48%

$GMAB

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

More Info: https://pryzm.ozmosi.com/product/21245

$ABBV

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

More Info: https://pryzm.ozmosi.com/product/21245

$OSTX OS Therapies presented P2 Osteosarcoma results on 2026-01-15 for OST31-164

More Info: https://pryzm.ozmosi.com/product/23166

Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

600 Warren Ave,
Spring Lake, NJ 07762